论文部分内容阅读
核医学的发展是跳跃式的,80年代开始了核医学的又一个飞跃——核肿瘤学。免疫学中单克隆抗体技术和完善的免疫蛋白标记技术的发展促进了核肿瘤学的发展。期望在80年代末期,放射性标记肿瘤单克隆抗体将用子许多常见实质肿瘤的常规诊断和治疗。PET(正电子发射断层摄影)给我们提供了观察体内肿瘤代谢的一种满意方法。相信5～7年后,建立在人类肿瘤PET显象基础上的人类肿瘤生物学将有较大发展。亲肿癌放射性药物肿瘤生物学的进展给核医学的发展铺设了道路,尤其是单克隆抗体技术制备放射性标记抗肿瘤抗体用作肿瘤显象和治疗。肿瘤的特异代谢特征也正被探索以提供新的显象方法。例如~(131)Ⅰ-碘胆固醇肾上腺肿瘤显象,~(131)Ⅰ-间位碘代(艹卡)胍作嗜铬细胞瘤显象并有可
The development of nuclear medicine is a leap. In the 1980s, another leap in nuclear medicine began, nuclear oncology. The development of immunological monoclonal antibody technology and sophisticated immune protein labeling technology has promoted the development of nuclear oncology. It is expected that in the late 1980s, radiolabeled tumor monoclonal antibodies would routinely diagnose and treat many common solid tumors. PET (Positron Emission Tomography) provides us with a satisfactory way to observe tumor metabolism in vivo. It is believed that 5 to 7 years later, the human tumor biology based on the PET imaging of human tumors will have greater development. Advances in tumor biology of radiopharmaceuticals for pro-tumor cancer paved the way for the development of nuclear medicine, and in particular, monoclonal antibody technology for the preparation of radiolabeled anti-tumor antibodies for tumor imaging and therapy. The specific metabolic features of tumors are also being explored to provide new imaging methods. For example, ~(131)I-iodolechol adrenal tumor imaging, ~(131)I-meta-position iodide (Leica) imaging for pheochromocytoma and there may be